Drugs / 177Lu-octreotate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02754297 | Apr 2016 → Apr 2025 overdue | carcinoid tumor, neuroendocrine carcinoma | CHU de Quebec-Universite Laval | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01842165 | May 2013 → Jan 2022 | digestive system neuroendocrine neoplasm | Jules Bordet Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-octreotate | “PRRT-naïve patients with progressive and/or symptomatic neuroendocrine tumour (NET) were scheduled to receive a four-cycle induction course of 177Lu-octreotate with...” PMID 30506283 ↗ Nov 2018 |
| Route | Intravenous | “injected intravenously” NCT01842165 ↗ |